FILE:CERN/CERN-8K-20040204162539.txt.gz
EVENTS:	Financial statements and exhibits	Regulation FD Disclosure
TEXT:
ITEM: Financial statements and exhibits
ITEM: Regulation FD Disclosure
Table of Contents
Date of report (Date of earliest event reported) February 4, 2004
Table of Contents
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
The following exhibit is furnished herewith.
99.1   Press Release issued February 4, 2004.
Item 9. Regulation FD Disclosure
Cerner Corporation is furnishing herewith as Exhibit 99.1, the Press Release issued by the Company on February 4, 2004, which announces the Company's financial results for the three months and twelve months ended January 3, 2004. This Press Release is being furnished under this Item 9 in accordance with SEC Release No. 33-8216 dated March 27, 2003.
To supplement our consolidated financial statements presented in accordance with GAAP, the Company uses non-GAAP measures of operating results, net income and earnings per share, which are adjusted from results based on GAAP to exclude certain expense items. The Company also discloses certain non-GAAP financial measures, such as booking revenue and revenue backlog. These non-GAAP measures are provided to enhance the user's overall understanding of our financial performance. These measurements are not recognized in accordance with GAAP and should not be viewed as an alternative to GAAP measures of performance.
The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, unless the registrant expressly states otherwise.
     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
Table of Contents

 
EXHIBIT 99.1
CONTACTS: INVESTORS: Allan Kells, (816) 201-2445 akells@cerner.com
MEDIA: Justin Scott, (816) 201-6438 jscott@cerner.com
CERNER'S INTERNET HOME PAGE: http://www.cerner.com
Cerner Corporation (NASDAQ:CERN) today announced results for the 2003 fourth quarter ended January 3, 2004. Diluted earnings per share were $0.44, compared to $0.27 in the fourth quarter of 2002. The fourth quarter of 2002 included a gain on the sale of WebMD stock and an impairment charge on various investments that, in aggregate, decreased EPS by $0.16. Analysts' consensus estimates for fourth quarter earnings per share were $0.43.
KANSAS CITY, Mo.  February 4, 2004 
Fourth quarter revenues increased 6 percent to $227.4 million compared to $215.0 million in the year-ago quarter. Net earnings in the quarter were $16.2 million, compared to $9.9 million in the fourth quarter of 2002. The aforementioned stock gain and impairment charges together reduced fourth quarter of 2002 net earnings by $5.8 million.
The Company generated operating cash flow of $41.8 million in the fourth quarter driven by strong cash collections and a significant number of implementations. For the year, operating cash flow totaled $133.6 million.
Cerner Millennium
Other Fourth Quarter Highlights:
"We are extremely pleased with our results in the fourth quarter," said Neal Patterson, Cerner's co-founder, Chairman and Chief Executive Officer. "Our results reflect our continued ability to generate strong levels of new business bookings and our focus on expanding operating margins and strengthening cash flow performance."
"We continued to expand our leadership position in the competitive healthcare information technology market," added Patterson. "Demand for healthcare information technology remains robust, and we believe we are well positioned to benefit from this demand because of our broad range of proven solutions."
 
Page 2  Cerner January 3, 2004
Future Period Guidance
Cerner expects earnings per share in the first quarter of 2004 to be between $0.30 and $0.32. The Company expects revenue in the first quarter to be approximately $215 million to $220 million. Cerner expects bookings revenue in the first quarter to be between $180 million and $200 million.
For 2004, the Company believes that analysts' earnings per share estimates between $1.60 and $1.65 are reasonable, which is up from previous guidance of $1.55 to $1.60. Cerner expects revenue for 2004 to be between $920 million and $940 million, which is $10 million higher than the Company's previous guidance range.
The Company also provided cash flow guidance for 2004, indicating that it expects to generate between $120 million and $140 million of operating cash flow. Based on these estimates, the Company expects to generate positive free cash flow, defined as operating cash flow less capital expenditures and capitalized software, in 2004.
Earnings Conference Call
Cerner will host an earnings conference call to provide additional detail at 3:30 p.m. CT on February 4, 2004. The dial-in number for the call is 617-786-2961 and the replay number is (617) 801-6888 (Pass code: 37491884). The call will also be Web cast and available both live and archived on Cerner's Web site at www.cerner.com in the Investors' section under News and Events. Please access the site fifteen minutes early to register and to download and install any necessary audio software. For those who cannot listen to the live broadcast, replays will be made available shortly after the call and will run for two weeks. A copy of the script used during the call will also be available at www.cerner.com in the Investors' section under News and Events.
Cerner Corporation is taking the paper chart out of health care, eliminating error, variance and unnecessary waste in the care process. With more than 1500 clients worldwide, Cerner is the leading supplier of health care information technology. The following are trademarks of Cerner: Cerner, Cerner's logo and Cerner Millennium. Nasdaq: CERN, www.cerner.com
This release may contain forward-looking statements that involve a number of risks and uncertainties. It is important to note that the Company's performance, financial condition or business could differ materially from those expressed in such forward-looking statements. The words "believe", "guidance", "expects", "estimates" and similar expressions are intended to identify such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: quarterly operating results may vary, stock price may be volatile, market risk of investments, potential impairment of goodwill, changes in the health care industry, significant competition, the Company's proprietary technology may be subjected to infringement claims or may be infringed upon, regulation of the Company's software by the U.S. Food and Drug Administration or other government regulation, the possibility of product-related liabilities, possible system errors or failures or defects in the performance of the Company's software, and risks associated with the Company's global operations. Additional discussion of these and other factors affecting the Company's business is contained in the Company's periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes in future operating results, financial condition or business over time.
 
 


